Actively Recruiting
The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients
Led by Radboud University Medical Center · Updated on 2025-02-05
690
Participants Needed
27
Research Sites
271 weeks
Total Duration
On this page
Sponsors
R
Radboud University Medical Center
Lead Sponsor
A
Amsterdam UMC, location VUmc
Collaborating Sponsor
AI-Summary
What this Trial Is About
The primary objective of this study is to compare the 3-year overall survival of stage III NSCLC patients during follow-up surveillance with 18F-Fluorodeoxyglucose Positron Emission Tomography/ Computerized Tomography (18F FDG PET/CT) versus follow-up with conventional CT surveillance. Participants will receive usual care until 3 years of follow-up (control group) with additional whole-body 18F FDG PET/CT scans during follow-up visits at 6 months, 12 months, 18 months, 24 months, and 36 months of follow-up in the intervention group. Other tasks include: * filling in quality of life (QOL) questionnaires at every time point; * participating in an interview evaluating the addition of the 18F FDG PET/CT scans (optional); * collecting blood at the follow-up time points for our secondary endpoint (optional). Researchers will compare the usual care control group with the intervention group to see if the additional 18F FDG PET/CT scans are (cost-)effective.
CONDITIONS
Official Title
The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Cytological or histologically proven stage III non-small cell lung cancer before start of curative intent treatment
- Treated with curative intent and started follow-up care
- All adjuvant treatments are permitted as co-intervention during follow-up care
- Age 18 years or older
- ECOG Performance Status classification 0-2 at moment of inclusion
- Written and signed informed consent by the patient or patient's representative
You will not qualify if you...
- Life expectancy shorter than 6 months at the end of curative intent treatment
- Evidence of recurrence after end of curative intent treatment and before randomization (4 months follow-up)
- Any condition that would interfere with evaluation of the intervention or study results as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 27 locations
1
Tergooi MC
Hilversum, Utrecht, Netherlands, 1212 VG
Actively Recruiting
2
Amsterdam UMC
Amsterdam, Netherlands
Actively Recruiting
3
Antoni van Leeuwenhoek/Nederlands Kanker Instituut
Amsterdam, Netherlands
Actively Recruiting
4
OLVG
Amsterdam, Netherlands
Actively Recruiting
5
Gelre Ziekenhuizen
Apeldoorn & Zutphen, Netherlands
Actively Recruiting
6
Amphia Ziekenhuis
Breda, Netherlands
Actively Recruiting
7
Deventer Ziekenhuis
Deventer, Netherlands
Actively Recruiting
8
Ziekenhuis Gelderse Vallei
Ede, Netherlands
Actively Recruiting
9
Máxima Medisch Centrum
Eindhoven & Veldhoven, Netherlands
Actively Recruiting
10
Treant
Emmen, Netherlands
Actively Recruiting
11
Medisch Spectrum Twente
Enschede, Netherlands
Actively Recruiting
12
Groene Hart Ziekenhuis
Gouda, Netherlands
Actively Recruiting
13
Martini Ziekenhuis
Groningen, Netherlands
Actively Recruiting
14
Tjongerschans ziekenhuis
Heerenveen, Netherlands
Actively Recruiting
15
Dijklander Ziekenhuis
Hoorn, Netherlands
Actively Recruiting
16
Canisius Wilhelmina Ziekenhuis
Nijmegen, Netherlands
Actively Recruiting
17
Radboudumc
Nijmegen, Netherlands
Actively Recruiting
18
Bravis Ziekenhuis
Roosendaal, Netherlands
Actively Recruiting
19
Maasstad ZIekenhuis
Rotterdam, Netherlands
Actively Recruiting
20
Franciscus Gasthuis & Vlietland
Schiedam, Netherlands
Actively Recruiting
21
Haaglanden Medisch Centrum
The Hague, Netherlands
Actively Recruiting
22
HagaZiekenhuis
The Hague, Netherlands
Actively Recruiting
23
Elisabeth-TweeSteden Ziekenhuis
Tilburg, Netherlands
Actively Recruiting
24
Diakonessenhuis
Utrecht, Netherlands
Actively Recruiting
25
UMC Utrecht
Utrecht, Netherlands
Actively Recruiting
26
St. Antonius Ziekenhuis
Utrecht & Nieuwegein, Netherlands
Actively Recruiting
27
Streekziekenhuis Koningin Beatrix
Winterswijk, Netherlands
Actively Recruiting
Research Team
N
NVALT31-PET study team
CONTACT
N
Nicole E. Billingy, MSc.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here